Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Other Working Capital Changes: 2013-2024

Historic Other Working Capital Changes for ImmunityBio (IBRX) over the last 12 years, with Dec 2024 value amounting to -$5.5 million.

  • ImmunityBio's Other Working Capital Changes fell 5.41% to $35,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.3 million, marking a year-over-year decrease of 136.76%. This contributed to the annual value of -$5.5 million for FY2024, which is 8.14% up from last year.
  • Per ImmunityBio's latest filing, its Other Working Capital Changes stood at -$5.5 million for FY2024, which was up 8.14% from -$6.0 million recorded in FY2023.
  • ImmunityBio's 5-year Other Working Capital Changes high stood at $16.6 million for FY2022, and its period low was -$6.0 million during FY2023.
  • Moreover, its 3-year median value for Other Working Capital Changes was -$5.5 million (2024), whereas its average is $1.7 million.
  • In the last 5 years, ImmunityBio's Other Working Capital Changes skyrocketed by 497.62% in 2022 and then slumped by 135.98% in 2023.
  • Yearly analysis of 5 years shows ImmunityBio's Other Working Capital Changes stood at -$5.6 million in 2020, then rose by 25.74% to -$4.2 million in 2021, then soared by 497.62% to $16.6 million in 2022, then slumped by 135.98% to -$6.0 million in 2023, then grew by 8.14% to -$5.5 million in 2024.